Cat. No. 4077
Chemical Name: 3-[5-(3-(3-Fluorophenyl)-3-oxoprope
Biological ActivitySelective inhibitor of class IIa histone deacetylases (HDACs). Exhibits tissue-selective inhibition between members of class II deacetylases in vivo; inhibits HDAC4 and HDAC5 in skeletal muscle and the heart without affecting HDAC3 activity. Arrests myogenesis through the stabilization of myocyte enhancer factor 2D (MEF2D)-HDAC3/4 complex. Displays no inhibition of class I HDAC activity or expression.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Nebbioso et al (2009) Selective class II HDAC inhibitors may impaor myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO J. 10 776.
Mai et al (2007) Identification of two new synthetic histone deacetylase inhibitors that modulate globin gene expression in erythroid cells from healthy donors and patients with thalassemia. Mol.Pharmacol. 72 1111. PMID: 17666592.
Mai et al (2005) Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamines. J.Med.Chem. 48 3344. PMID: 15857140.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses MC 1568 from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: MC 1568, supplier, MC1568, HDAC, selective, inhibitors, inhibits, histone, deacetylase, class, II, IIa, HDAC4, epigenetics, Tocris Bioscience, Histone Deacetylase Inhibitor products
Find multiple products by catalog number
New Products in this Area
HDAC5 and HDAC9 inhibitorMC 1742
Potent class I and IIb HDAC inhibitorYK 3-237
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.